by GlyTherix | May 1, 2024
Meet with targeted radiotherapy company GlyTherix Ltd in Boston and New York. Next week Brad Walsh, CEO and David Burdis, CFO will be joining with their advisors Atoll Financial Group for a roadshow in Boston Monday May 6 and Tuesday May 7 followed by New York May 8...
by GlyTherix | Apr 3, 2024
Sydney (Australia) – April 3, 2024. GlyTherix Ltd (GlyTherix) an Australian immuno-oncology company specialising in developing targeted radiotherapies for solid tumors today announces that Dr Colin Hayward has joined GlyTherix’s Clinical Advisory Board. Based in North...
by GlyTherix | Feb 22, 2024
GlyTherix is pleased to announce Dr Brad Walsh will be presenting the GlyTherix Ltd story at 1.15pm on Friday March 1 at the B. Riley Securities Radiopharma Day. Email radiopharma@brileyfin.com for more...
by GlyTherix | Feb 21, 2024
GlyTherix Ltd is pleased to announce Alan Harris MD PhD has taken an expanded role as a Strategic and Scientific Advisor to assist the company increase its current US footprint including retention of key US-based personnel. He will work closely with GlyTherix’s Dr...
by GlyTherix | Feb 16, 2024
GlyTherix Ltd is pleased to advise it has appointed Atoll Financial Group as its financial advisor for its Series B raise of up to USD50M. This round will enable the company to push forward its targeted radiotherapy program Phase 1b trial and includes funding for its...
by GlyTherix | Jan 8, 2024
GlyTherix Ltd is so pleased to announce another esteemed clinician has joined our advisory board. Elcin Zan, MD is a dual board-certified radiologist specializing in Nuclear Medicine and Neuroradiology. She is an Assistant Professor of Clinical Radiology at Weill...
